vs
Side-by-side financial comparison of Global Business Travel Group, Inc. (GBTG) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Global Business Travel Group, Inc. is the larger business by last-quarter revenue ($792.0M vs $622.0M, roughly 1.3× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 10.5%, a 24.0% gap on every dollar of revenue. On growth, Global Business Travel Group, Inc. posted the faster year-over-year revenue change (34.0% vs 4.8%). Over the past eight quarters, Global Business Travel Group, Inc.'s revenue compounded faster (13.9% CAGR vs 4.6%).
A travel management company (TMC) is a travel agency which manages organizations' corporate or business travel programs. Such companies will often provide an end-user online booking tool, mobile application, program management, and consulting teams, executive travel services, meetings and events support, reporting functionality, duty of care, and more. Non-Profit travel management companies also provide services to manage complex visa requirements, pre-trip medical needs, remote area travel, ...
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
GBTG vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $792.0M | $622.0M |
| Net Profit | $83.0M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 3.7% | 62.4% |
| Net Margin | 10.5% | 34.4% |
| Revenue YoY | 34.0% | 4.8% |
| Net Profit YoY | 692.9% | 2.9% |
| EPS (diluted) | $0.16 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $792.0M | $622.0M | ||
| Q3 25 | $674.0M | $609.3M | ||
| Q2 25 | $631.0M | $578.7M | ||
| Q1 25 | $621.0M | $568.2M | ||
| Q4 24 | $591.0M | $593.6M | ||
| Q3 24 | $597.0M | $564.7M | ||
| Q2 24 | $625.0M | $537.3M | ||
| Q1 24 | $610.0M | $568.0M |
| Q4 25 | $83.0M | $214.2M | ||
| Q3 25 | $-62.0M | $288.2M | ||
| Q2 25 | $15.0M | $30.2M | ||
| Q1 25 | $75.0M | $238.3M | ||
| Q4 24 | $-14.0M | $208.2M | ||
| Q3 24 | $-128.0M | $544.0M | ||
| Q2 24 | $27.0M | $102.0M | ||
| Q1 24 | $-19.0M | $4.8M |
| Q4 25 | 3.7% | 62.4% | ||
| Q3 25 | 1.8% | 70.1% | ||
| Q2 25 | 5.4% | 36.3% | ||
| Q1 25 | 8.9% | 94.0% | ||
| Q4 24 | 5.1% | 60.9% | ||
| Q3 24 | 4.5% | — | ||
| Q2 24 | 6.7% | 50.2% | ||
| Q1 24 | 2.6% | -13.0% |
| Q4 25 | 10.5% | 34.4% | ||
| Q3 25 | -9.2% | 47.3% | ||
| Q2 25 | 2.4% | 5.2% | ||
| Q1 25 | 12.1% | 41.9% | ||
| Q4 24 | -2.4% | 35.1% | ||
| Q3 24 | -21.4% | 96.3% | ||
| Q2 24 | 4.3% | 19.0% | ||
| Q1 24 | -3.1% | 0.8% |
| Q4 25 | $0.16 | $0.49 | ||
| Q3 25 | $-0.13 | $0.67 | ||
| Q2 25 | $0.03 | $0.07 | ||
| Q1 25 | $0.16 | $0.55 | ||
| Q4 24 | $-0.04 | $0.46 | ||
| Q3 24 | $-0.28 | $1.21 | ||
| Q2 24 | $0.06 | $0.23 | ||
| Q1 24 | $-0.04 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $434.0M | $618.7M |
| Total DebtLower is stronger | $1.4B | $9.0B |
| Stockholders' EquityBook value | $1.6B | $9.7B |
| Total Assets | $4.9B | $19.6B |
| Debt / EquityLower = less leverage | 0.88× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $434.0M | $618.7M | ||
| Q3 25 | $427.0M | $938.9M | ||
| Q2 25 | $601.0M | $631.9M | ||
| Q1 25 | $552.0M | $1.1B | ||
| Q4 24 | $536.0M | $929.0M | ||
| Q3 24 | $524.0M | $950.1M | ||
| Q2 24 | $515.0M | $1.8B | ||
| Q1 24 | $475.0M | $843.0M |
| Q4 25 | $1.4B | $9.0B | ||
| Q3 25 | $1.4B | $8.9B | ||
| Q2 25 | $1.4B | $8.0B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.4B | $7.6B | ||
| Q3 24 | $1.4B | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $1.6B | $9.7B | ||
| Q3 25 | $1.5B | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.1B | $9.8B | ||
| Q4 24 | $1.1B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $1.2B | $9.8B | ||
| Q1 24 | $1.2B | $9.9B |
| Q4 25 | $4.9B | $19.6B | ||
| Q3 25 | $4.8B | $19.3B | ||
| Q2 25 | $3.9B | $18.3B | ||
| Q1 25 | $3.8B | $17.6B | ||
| Q4 24 | $3.6B | $18.2B | ||
| Q3 24 | $3.8B | $18.0B | ||
| Q2 24 | $3.8B | $17.7B | ||
| Q1 24 | $3.8B | $16.1B |
| Q4 25 | 0.88× | 0.92× | ||
| Q3 25 | 0.91× | 0.93× | ||
| Q2 25 | 1.15× | 0.84× | ||
| Q1 25 | 1.23× | 0.78× | ||
| Q4 24 | 1.32× | 0.74× | ||
| Q3 24 | 1.26× | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $52.0M | $827.1M |
| Free Cash FlowOCF − Capex | $13.0M | — |
| FCF MarginFCF / Revenue | 1.6% | — |
| Capex IntensityCapex / Revenue | 4.9% | — |
| Cash ConversionOCF / Net Profit | 0.63× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $104.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.0M | $827.1M | ||
| Q3 25 | $71.0M | $702.6M | ||
| Q2 25 | $57.0M | $364.0M | ||
| Q1 25 | $53.0M | $596.1M | ||
| Q4 24 | $65.0M | $742.5M | ||
| Q3 24 | $85.0M | $703.6M | ||
| Q2 24 | $73.0M | $658.2M | ||
| Q1 24 | $49.0M | $664.6M |
| Q4 25 | $13.0M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $27.0M | — | ||
| Q1 25 | $26.0M | — | ||
| Q4 24 | $33.0M | — | ||
| Q3 24 | $59.0M | — | ||
| Q2 24 | $49.0M | — | ||
| Q1 24 | $24.0M | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | 9.9% | — | ||
| Q2 24 | 7.8% | — | ||
| Q1 24 | 3.9% | — |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | 4.3% | — | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 4.4% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | 0.63× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 3.80× | 12.06× | ||
| Q1 25 | 0.71× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 2.70× | 6.45× | ||
| Q1 24 | — | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GBTG
| Travel | $620.0M | 78% |
| Other | $172.0M | 22% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
